APA (7th ed.) Citation

Banerjee, S., Rustin, G., Paul, J., Williams, C., Pledge, S., Gabra, H., . . . Kaye, S. B. (2013). A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: An SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG. Annals of Oncology, 24(3), 679. https://doi.org/10.1093/annonc/mds494

Chicago Style (17th ed.) Citation

Banerjee, S., et al. "A Multicenter, Randomized Trial of Flat Dosing Versus Intrapatient Dose Escalation of Single-agent Carboplatin as First-line Chemotherapy for Advanced Ovarian Cancer: An SGCTG (SCOTROC 4) and ANZGOG Study on Behalf of GCIG." Annals of Oncology 24, no. 3 (2013): 679. https://doi.org/10.1093/annonc/mds494.

MLA (9th ed.) Citation

Banerjee, S., et al. "A Multicenter, Randomized Trial of Flat Dosing Versus Intrapatient Dose Escalation of Single-agent Carboplatin as First-line Chemotherapy for Advanced Ovarian Cancer: An SGCTG (SCOTROC 4) and ANZGOG Study on Behalf of GCIG." Annals of Oncology, vol. 24, no. 3, 2013, p. 679, https://doi.org/10.1093/annonc/mds494.